Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05109065 · ClinicalTrials.gov registry record
Peripheral Immune System in Individuals With Schizophrenia
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 63
- Enrollment target
NCT05109065: Completed study, sponsored by Stanford University.
NCT05109065 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05109065 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
The investigators are seeking healthy volunteers and people with schizophrenia or schizoaffective disorder for a clinical study of the immune system in psychotic disorders. This is an observational study, to understand the ways in which the immune system may be contributing to the disease process.
Primary Outcome
Measure the concentration of complement 4 protein in immune cells.
Interventions
- DIAGNOSTIC_TEST Vitals
- DIAGNOSTIC_TEST SCID (Standardized Clinical Interview for DSM-V)
- DIAGNOSTIC_TEST PSS (Perceived Stress Score)
- DIAGNOSTIC_TEST Urine Toxicology Screen
- DIAGNOSTIC_TEST Blood Work
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2024-05-23 |
What the finished NCT05109065 record still lists
NCT05109065 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Vitals is the first listed.
NCT05109065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05109065 about?
NCT05109065 is a clinical study titled "Peripheral Immune System in Individuals With Schizophrenia". The investigators are seeking healthy volunteers and people with schizophrenia or schizoaffective disorder for a clinical study of the immune system in psychotic disorders. This is an observational study, to understand the ways in which the immune system may be contributing to the disease process.
What is the current status of trial NCT05109065?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2021-03-01. Estimated completion is 2024-05-23.
What interventions are being tested in trial NCT05109065?
The interventions under investigation include: Vitals (DIAGNOSTIC_TEST), SCID (Standardized Clinical Interview for DSM-V) (DIAGNOSTIC_TEST), PSS (Perceived Stress Score) (DIAGNOSTIC_TEST), Urine Toxicology Screen (DIAGNOSTIC_TEST), Blood Work (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05109065?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI